Home › Compare › DTCFF vs GBDC

DTCFF vs GBDC: Dividend Comparison 2026

DTCFF yields 500.00% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DTCFF wins by $61378.67M in total portfolio value
10 years
DTCFF
DTCFF
● Live price
500.00%
Share price
$0.40
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$61399.52M
Annual income
$44,063,578,515.70
Full DTCFF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — DTCFF vs GBDC

📍 DTCFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDTCFFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DTCFF + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
DTCFF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DTCFF
Annual income on $10K today (after 15% tax)
$42,500.00/yr
After 10yr DRIP, annual income (after tax)
$37,454,041,738.34/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, DTCFF beats the other by $37,440,058,614.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DTCFF + GBDC for your $10,000?

DTCFF: 50%GBDC: 50%
100% GBDC50/50100% DTCFF
Portfolio after 10yr
$30710.19M
Annual income
$22,040,014,624.77/yr
Blended yield
71.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

DTCFF
No analyst data
Altman Z
-31.5
Piotroski
1/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DTCFF buys
0
GBDC buys
0
No recent congressional trades found for DTCFF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDTCFFGBDC
Forward yield500.00% ✓11.86%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$61399.52M ✓$20.85M
Annual income after 10y$44,063,578,515.70 ✓$16,450,733.83
Total dividends collected$59892.67M ✓$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: DTCFF vs GBDC ($10,000, DRIP)

YearDTCFF PortfolioDTCFF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$60,700$50,000.00$12,492$1,791.70+$48.2K → DTCFF
2$348,594$283,644.86$16,527$3,160.58+$332.1K → DTCFF
3$1,895,372$1,522,376.89$23,588$5,904.90+$1.87M → DTCFF
4$9,763,990$7,735,942.00$37,141$11,901.65+$9.73M → DTCFF
5$47,691,977$37,244,507.54$66,205$26,463.38+$47.63M → DTCFF
6$221,049,019$170,018,603.23$137,452$66,612.65+$220.91M → DTCFF
7$972,993,924$736,471,474.07$342,372$195,298.53+$972.65M → DTCFF
8$4,070,762,075$3,029,658,575.98$1,053,292$686,954.33+$4069.71M → DTCFF
9$16,201,818,371$11,846,102,950.68$4,111,439$2,984,416.95+$16197.71M → DTCFF
10$61,399,524,173$44,063,578,515.70$20,849,974$16,450,733.83+$61378.67M → DTCFF

DTCFF vs GBDC: Complete Analysis 2026

DTCFF — Stock

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Full DTCFF Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this DTCFF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DTCFF vs SCHDDTCFF vs JEPIDTCFF vs ODTCFF vs KODTCFF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.